Experimental combo aims to control MDS without transplant
NCT ID NCT07238686
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of venetoclax (a targeted drug), standard chemotherapy (azacitidine or decitabine), and an infusion of immune cells from a partially matched donor for people with intermediate- or high-risk myelodysplastic syndromes (MDS) who cannot or choose not to have a bone marrow transplant. The study will enroll 40 participants and measure overall survival and response rates. The goal is to see if this approach can control the disease safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax, azacitidine or decitabine, and donor immune cells
What this could lead to
If it works, this could offer a new treatment option for people with higher-risk MDS who cannot have a standard bone marrow transplant.
What could go wrong
This is a small, early-phase trial (40 people) testing a complex combination. It may not work better than existing treatments, and there are risks of infection, bleeding, or graft-versus-host disease from the donor cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••